Undisclosed anti-MSLN×CDH3 bsADC
/ Biocytogen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
A novel MSLN×CDH3 bispecific antibody-drug conjugate (BsADC) demonstrates promising anti-tumor efficacy
(AACR 2026)
- "In vivo, we also tested the efficacy of the MSLN×CDH3 bsAb conjugated to BLD1102. Both anti-MSLN×CDH3 bsADC (MMAE) and anti-MSLN×CDH3 bsADC (BLD1102) exhibited superior efficacy in patient-derived ovarian and pancreatic ductal adenocarcinoma xenograft models.Conclusion Together, these results suggest that anti-MSLN×CDH3 bsADC has the potential to be a novel therapeutic alternative for MSLN and CDH3-expressing tumors."
ADC • Bispecific • Clinical • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CDH3 • MSLN
1 to 1
Of
1
Go to page
1